Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines.
BACKGROUND
Chronic myeloid leukaemia (CML) is characterized by the expression of the BCR/ABL1 fusion gene, a constitutively activated tyrosine kinase that commonly results from the formation of the Philadelphia (Ph) chromosome after a t(9;22)(q34;q11) or variant rearrangement. The duplication of the Ph chromosome is a recurring abnormality acquired during disease progression, whereas intrachromosomal amplification of BCR/ABL1 is a rare phenomenon and has been associated with imatinib therapy resistance. Archival bone marrow chromosome suspensions from 19 CML patients known to carry more than 1 copy of BCR/ABL1 and 10 CML cell lines were analyzed by fluorescent in situ hybridization with a panel of probes from 9q34.1-qter to investigate whether they carried two identical copies of the Ph chromosome or, instead, one or both Ph contained cryptic imbalances of some regions.


RESULTS
A duplication of the entire Ph chromosome with no further events involving the derivative 22 was found in 12 patients. In contrast, a sideline with either 1 or 2 isochromosomes of the Ph chromosome was identified in 6 patients but none of the cell lines. In one of the patients a translocation between the distal end of one arm of the isoderivative chromosome 22 and a third chromosome was revealed. 2 patients were found to carry marker structures harbouring high copy number gains of BCR/ABL1 fusion along with a variable part of 9q34 region downstream of ABL1 breakpoint, similarly to the markers present in the imatinib resistant cell line K562. We identified the following regions of amplification: 9q34.1 → q34.2 and 9q34.1 → qter, with a common minimum amplified region of 682 Kb. One of the patients had 5 BCR/ABL1 positive clones with variable level of 9q34 amplifications on a variety of structures, from an isoderivative 22 to tandem duplications.


CONCLUSIONS
These data confirm that the intrachromosomal genomic amplification of BCR/ABL1 that occurs in some CML patients during disease progression also involves amplification of 9q34 gene-rich sequences downstream of ABL1 breakpoint. The variety of rearrangements identified in this relatively small cohort demonstrates that the Ph chromosome is not a stable structure but prone to further rearrangements during disease progression.
Virgili
Anna
A
Academic Haematology, University College London Cancer Institute, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK. e.nacheva@ucl.ac.uk.
Nacheva
Elisabeth P
EP
Science. 2001 Aug 3;293(5531):876-80
11423618
Nat Rev Cancer. 2007 Jun;7(6):441-53
17522713
Blood. 2009 Feb 19;113(8):1619-30
18827185
Genes Chromosomes Cancer. 2007 Nov;46(11):1039-50
17696194
Cancer Genet Cytogenet. 1993 Apr;66(2):113-6
8500097
Cancer Genet Cytogenet. 2003 Jun;143(2):140-4
12781448
Mol Cytogenet. 2008 Jul 18;1:14
18638369
Eur J Haematol. 2003 Apr;70(4):235-9
12656747
Cancer Genet Cytogenet. 2008 Jan 1;180(1):60-4
18068536
Cancer Genet Cytogenet. 2010 May;199(1):66-8
20417874
Cancer Genet Cytogenet. 2000 Apr 1;118(1):1-8
10731582
Cancer Genet Cytogenet. 2005 Jun;159(2):164-7
15899391
Cancer Genet Cytogenet. 2007 Apr 15;174(2):132-7
17452255
Leukemia. 2001 Nov;15(11):1795-7
11681425
Cancer Genet Cytogenet. 2002 Nov;139(1):30-3
12547154
Genes Chromosomes Cancer. 2001 May;31(1):10-4
11284030
Leukemia. 2002 Nov;16(11):2190-6
12399961